BCA
ABBV icon

Benchmark Capital Advisors’s AbbVie ABBV Stock Holding History

Benchmark Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,050
Closed -$982K – 137
2017
Q3 		$982K Buy
11,050
+200
+2% +$15.2K 0.76% 43
2017
Q2 		$787K Buy
+10,850
New +$729K 0.62% 47

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Benchmark Capital Advisors's ABBV Position: Q4 2017 in Review

Benchmark Capital Advisors sold out of AbbVie (ABBV) in Q4 2017, closing a stake of 11,050 shares — an estimated $982K sold.

Benchmark Capital Advisors first reported a position in ABBV in Q2 2017 and held it in 2 quarters. The position peaked at $982K in Q3 2017. 2,001 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

  • Benchmark Capital Advisors reported no remaining AbbVie position as of Q4 2017 after selling out during the quarter.
  • Benchmark Capital Advisors sold 11,050 AbbVie shares in Q4 2017, an estimated $982K.
  • Benchmark Capital Advisors first reported a position in AbbVie in Q2 2017 and held it in 2 quarters.
  • Benchmark Capital Advisors's AbbVie position peaked at $982K in Q3 2017.
  • 2,001 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on Benchmark Capital Advisors's 13F filing for Q4 2017, filed 7 Feb 2018.